F. Carbonnel
Oncology · 2017–2018
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 72 citations into it
Whom F. Carbonnel trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from F. Carbonnel's perspective
Ordered by how strongly the researchers F. Carbonnel trusts endorse each paper. Same corpus, a different order for every researcher.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody (Science Translational Medicine)
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (Nature Communications)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (The Lancet Oncology)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (Journal of Clinical Oncology)